Suchergebnisse - "Nordberg, Lena Bugge"

PubPharm (14)

1

Subclinical inflammation and joint damage progression in patients with early RA fulfilling 2011 vs 2022 ACR/EULAR Boolean remission criteria : data from the ARCTIC study

enthalten in: Annals of the rheumatic diseases | 2024

von Melokhina, V. | Paulshus Sundlisæter, N. | Sexton, J. | +7

2

Performance of the Rheumatoid Arthritis Impact of Disease (RAID) score in relation to flares in disease activity

enthalten in: RMD open | 2024

von Holten, K. | Paulshus Sundlisæter, N. | Sexton, J. | +18

3

Rheumatology congresses post COVID-19 : we cannot regress

enthalten in: The Lancet. Rheumatology | 2023

von Nordberg, L. | Vikse, J. | Heiberg, M. | +5

4

CXCL16 associates with adverse outcome and cardiac involvement in hospitalized patients with Covid-19

enthalten in: The Journal of infection | 2022

von Gregersen, I. | Ueland, T. | Holter, J. | +20

CommentOn: J Infect. 2022 Nov;85(5):573-607. - PMID 36041645

5

High Circulating Levels of the Homeostatic Chemokines CCL19 and CCL21 Predict Mortality and Disease Severity in COVID-19

enthalten in: The Journal of infectious diseases | 2022

von Tveita, A. | Murphy, S. | Holter, J. | +109

6

Fatigue in patients with early rheumatoid arthritis undergoing treat-to-target therapy : predictors and response to treatment

enthalten in: Annals of the rheumatic diseases | 2022

von Holten, K. | Paulshus Sundlisater, N. | Lillegraven, S. | +8

7

Persistent pulmonary pathology after COVID-19 is associated with high viral load, weak antibody response, and high levels of matrix metalloproteinase-9

enthalten in: Scientific reports | 2021

von Lerum, T. | Maltzahn, N. | Aukrust, P. | +74

8

Evaluation of the Effects of Remdesivir and Hydroxychloroquine on Viral Clearance in COVID-19 : A Randomized Trial

enthalten in: Annals of internal medicine | 2021

von Barratt-Due, A. | Olsen, I. | Nezvalova-Henriksen, K. | +111

9

Value of MRI and ultrasound for prediction of therapeutic response and erosive progression in patients with early rheumatoid arthritis managed by an aggressive treat-to-target strategy

enthalten in: RMD open | 2021

von Sundin, U. | Sundlisater, N. | Aga, A. | +18

10

Comparing the disease course of patients with seronegative and seropositive rheumatoid arthritis fulfilling the 2010 ACR/EULAR classification criteria in a treat-to-target setting : 2-year data from the ARCTIC trial

enthalten in: RMD open | 2018

von Nordberg, L. | Lillegraven, S. | Aga, A. | +8